Effective January 1st, Genentech will be updating the co-pay program benefit period. The program will be moving from a 12-month benefit to a calendar year benefit (January to December).
Patient benefit will automatically renew annually for all patients enrolled in the program on January 1st.
For more information, please call the Help Desk at 855-722-6729.
Now FDA-approved for another indication. Please see the Prescribing Information for additional information on the indication and call (855) RA-COPAY (855-722-6729) for information on the co-pay program.
The information contained in this section of the site is intended for US health care professionals only. Click “OK” if you are a health care professional or specialty pharmacy representative.
The information contained in this section of the site is intended for specialty pharmacy representatives only. Click “OK” if you are a health care professional or specialty pharmacy representative.
The information contained in this section of the site is intended for US health care professionals and specialty pharmacy representatives only. Click “OK” if you are a health care professional or specialty pharmacy representative.
*The final amount owed by patients may be as little as $5, but may vary depending on the patient's health insurance plan. Eligible commercially insured patients who are prescribed ACTEMRA or Rituxan for an FDA-approved use can receive up to $15,000 in assistance per 12-month period for drug costs and/or up to $2,000 in infusion assistance per 12-month period for Rituxan infusion costs. See terms and conditions for each program. Program limits apply.
ACTEMRA is a prescription medicine used:
It is not known if ACTEMRA is safe and effective in children with PJIA or SJIA under 2 years of age or in children with conditions other than PJIA or SJIA.
ACTEMRA can cause serious side effects
ACTEMRA changes the way your immune system works. This can make you more likely to get infections or make any current infection worse. Some people have died from these infections. Your healthcare provider should test you for TB before starting and during treatment with ACTEMRA.
Do not take ACTEMRA if you are allergic to tocilizumab, or any of the ingredients in ACTEMRA.
ACTEMRA can cause other serious side effects. These include:
Tears (perforation) of the Stomach or Intestines
If you have diverticulitis (inflammation in parts of the large intestine), talk to your healthcare provider before taking ACTEMRA. Some people taking ACTEMRA may develop a hole in the wall of their stomach or intestines (also known as a perforation).
Liver problems (Hepatotoxicity)
Some people have experienced serious life-threatening liver problems, which required a liver transplant or led to death. Your healthcare provider may tell you to stop taking ACTEMRA if you develop new or worsening liver problems during treatment with ACTEMRA.
Changes in Blood Test Results
Your healthcare provider should do blood tests before and after you start receiving ACTEMRA. You should not receive ACTEMRA if your neutrophil and platelet counts are too low or your liver function test levels are too high. These may cause your healthcare provider to stop your ACTEMRA treatment for a time or change your dose.
ACTEMRA may increase your risk of certain cancers by changing the way your immune system works.
Hepatitis B Infection
If you have or are a carrier of the hepatitis B virus (a virus that affects the liver), the virus may become active while you use ACTEMRA. Your healthcare provider may do blood tests before you start treatment with ACTEMRA and while you are using ACTEMRA.
Serious Allergic Reactions
Serious allergic reactions, including death, can happen with ACTEMRA. These reactions can happen with any infusion or injection of ACTEMRA, even if they did not occur with an earlier infusion or injection.
Nervous System Problems
While rare, Multiple Sclerosis has been diagnosed in people who take ACTEMRA.
The most common side effects of ACTEMRA include:
ACTEMRA & Pregnancy
Tell your healthcare provider if you are planning to become pregnant, are pregnant, plan to breast-feed, or are breast-feeding. If you are pregnant and taking ACTEMRA, join the pregnancy registry. To learn more, call 1-877-311-8972 or talk to your healthcare provider to register.
Tell your healthcare provider if you have any side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Genentech at 1-888-835-2555.
Rituxan is a prescription medicine used to treat:
Adults with Rheumatoid arthritis (RA): with another prescription medicine called methotrexate, to reduce the signs and symptoms of moderate to severe active RA, after treatment with at least one other medicine called a tumor necrosis factor (TNF) antagonist has been used and did not work well enough.
People with Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) ages 2 years and above: with glucocorticoids.
Adults with Pemphigus Vulgaris (PV): to treat moderate to severe PV.
Rituxan is not indicated in children less than 2 years of age with GPA or MPA or in children with conditions other than GPA or MPA.
What is the most important information I should know about Rituxan?
Rituxan can cause serious side effects that can lead to death, including:
Before receiving Rituxan, patients should tell their healthcare provider if they:
What are the possible side effects of Rituxan?
Rituxan can cause serious and life-threatening side effects, including:
What are common side effects during treatment with Rituxan?
The most common side effects of Rituxan include:
In adults with GPA or MPA, the most common side effects of Rituxan also include:
Other side effects with Rituxan include:
These are not all of the possible side effects with Rituxan.
Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.